ADARx Pharmaceuticals announces additional funding for clinical trials in HAE and other conditions

ADARx Pharmaceuticals announces additional funding for clinical trials in HAE and other conditions

ADARx Pharmaceuticals, a clinical-stage biotechnology company developing next-generation RNA therapeutics, has announced the successful close of a $200 million Series C financing.

The proceeds from the Series C financing will be used to further advance ADARx clinical programs, including ADX-324 and ADX-038. ADX-324 represents an innovative approach for the treatment of hereditary angioedema, a rare genetic disease that causes painful, rapid, and potentially life-threatening swelling attacks.

Dr. Zhen Li, President and Chief Executive Officer of ADARx Pharmaceuticals, said: “The strong support from our new and existing investors is a testament to the significant progress we have made in advancing next-generation RNA therapeutics for hepatic and extrahepatic targets.

“The early phase 1 clinical data strongly supports the potential of ADX-324 for patients suffering from hereditary angioedema. Moreover, the clinical data validate our proprietary targeted delivery PLR™ platform and our broad SPE™ technology. With this financing, we are well-positioned to achieve our clinical milestones for multiple clinical programs and to build a leading company in RNA therapeutics.”

(Source: ADARx Pharmaceuticals Inc)